Plus Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Cerenome

30/05/2025 15:02

Plus Therapeutics Inc PSTV.OQ PSTV.O is expected to show a fall in quarterly revenue when it reports  results on June 2 (estimated) for the period ending March 31 2025

The Austin Texas-based  company is expected to report a 11.5% decrease in revenue to $1.483 million from $1.68 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Plus Therapeutics Inc is for a loss of 15 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 25.7% in the last three months. ​

Wall Street's median 12-month price target for Plus Therapeutics Inc is $5.50​, above​ its last closing price of $0.29. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.43
-0.50
-0.49
Beat
1.3
Sep. 30 2024
-0.51
-0.56
-0.37
Beat
34.2
Jun. 30 2024
-0.46
-0.53
-0.56
Missed
-5.7​
Mar. 31 2024
-1.08
-1.09
-0.75
Beat
31.2
​​Dec. 31 2023
-0.83
-1.07
-0.84
Beat
21.7
Sep. 30 2023
-1.02
-1.12
-1.00
Beat
10.9​
Jun. 30 2023
-1.93
-1.91
-0.59
Beat
69.2
Mar. 31 2023
-1.91
-1.90
-2.10
Missed
-10.5

This summary was machine generated May 30 at 14:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)